Company & Business Profile
Laurus Labs Limited (“Laurus Labs”) was originally incorporated on September 19, 2005 at Hyderabad, Andhra Pradesh as a Private Limited Company. The company was subsequently converted into a public limited company and its name was changed to Laurus Labs Limited. The name of the company was changed to Aptuit Laurus Limited consequent to the strategic partnership entered into by the company with Aptuit Singapore. Thereafter the company was converted into a private limited company and its name was changed to Aptuit Laurus Private Limited. Subsequently the name of the company was changed to Laurus Labs Private Limited consequent to the proposed dilution of the shareholding of Aptuit Singapore in the company. The company was converted into a public limited company and the name of the company was changed to Laurus Labs Limited.
Laurus Labs Limited is the leading research and development (R&D) driven pharmaceutical company in India, with a leadership position in Generic Active Pharmaceutical Ingredients (APIs) for select, high-growth Therapeutic areas of Anti-Retrovirals (ARVs) and Hepatitis C.
The company also manufacture APIs in Oncology and other Therapeutic areas. The strategic and early investments in R&D and Manufacturing infrastructure have enabled them to become one of the leading suppliers of APIs in the ARV therapeutic area to multi-national pharmaceutical formulation companies which cater to the large and fast-growing “Donor-Funded Access-to-Medicines Markets” of Sub-Saharan Africa, South-East Asia and Latin America.
During the financial year 2016, Laurus Labs Limited sold their APIs in 32 countries. The company also has growing Synthesis and Nutraceutical/Cosmeceutical Ingredients businesses. Further, they are increasingly focusing towards growing their integrated generics Finished Dosage Forms (FDFs) business.
- Leadership in APIs in select, high growth therapeutic areas.
- Strong R&D capabilities and process chemistry skills.
- Industry leading, modern and regulatory compliant manufacturing capacities.
- Long-standing relationships with multi-national pharmaceutical companies.
- Experienced promoters and qualified operational personnel.
- Established track record of delivering growth.
Objects of the Issue
- To pre-payment of term loans.
- To general corporate purposes.
The equity shares of the company are proposed to be listed on the Bombay Stock Exchange (BSE) and National Stock Exchange (NSE).
Apply in IPO now in ASBA mode, to apply call us at 0731-4217261.